| REVIEW |
|
| Year : 2017 | Volume
: 2
| Issue : 1 | Page : 7-11 |
|
|
Impact of incretin-related agents on endothelial cell function
Hiroshi Nomoto1, Hideaki Miyoshi M.D., Ph.D. 1, Akinobu Nakamura1, Tatsuya Atsumi1, Naoki Manda2, Yoshio Kurihara3, Shin Aoki4, on behalf of SAIS Study Group5
1 Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
2 Manda Memorial Hospital, Sapporo, Japan
3 Kurihara Clinic, Sapporo, Japan
4 Aoki Clinic, Sapporo, Japan
5 The membership of the SAIS Study Group is provided in the Acknowledgements
Correspondence Address:
Hideaki Miyoshi
Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo
Japan
 Source of Support: This work was supported by The Japan Diabetes Foundation Inc. and The Waksman Foundation of Japan Inc.
, Conflict of Interest: None  | Check |
DOI: 10.4103/2542-3975.202726
|
|
|
Incretin-related drugs, such as dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) analogues, have been clinically available and widely used to treat patients with type 2 diabetes mellitus. Accumulating evidence indicates that these agents exert glycemic control and have various other favorable effects, including prevention of atherosclerosis. It is important to assess and manage early-phase atherosclerosis, but whether diabetic therapeutics including incretin-related drugs improve or maintain vascular endothelial cell function has not been fully determined. We previously published prospective clinical trials focused on flow-mediated dilation in patients with type 2 diabetes, who did not have severe atherosclerosis, using two different incretin-related drugs: a DPP-4 inhibitor and a GLP-1 analogue. These trials showed that these therapeutic agents did not improve endothelial cell function. In this article, we discuss how incretin-related drugs contribute, if at all, to vascular endothelial cell function, atherosclerosis, and beta-cell function, based on our clinical trials and previous evidence. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
![JOURNAL_FULL_NAME]](images/logo.gif){kind=logo}
